Form 4: Lipocine Inc. Director Jill M. Jene Acquires Stock Options
SEC Form 4 Filing
Director Jill M. Jene acquired stock options in Lipocine Inc. on June 5, 2024.
Summary
- On June 5, 2024, Jill M. Jene, a director of Lipocine Inc., acquired 1,764 stock options at an exercise price of $7.05.
- Following this transaction, Jene directly owns 5,410 derivative securities.
- The stock options vest 100% one year from the grant date and expire on June 5, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a transaction. The acquisition of stock options by a director could be interpreted as a positive sign, but without further context, it's difficult to gauge the overall impact.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of transaction: Jill M. Jene acquired stock options. |
| 06/05/2025 | Date the stock options vest 100%. |
| 06/05/2034 | Expiration date of the stock options. |
| 06/07/2024 | Date of signature on the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.